Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Syros Pharmaceuticals Inc (SYRS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 1.860x
Based on the latest financial reports, Syros Pharmaceuticals Inc (SYRS) has a cash flow conversion efficiency ratio of 1.860x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.69 Million) by net assets ($-11.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Syros Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Syros Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Syros Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syros Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
74SW
PA:74SW
|
0.160x |
|
Lanbay Inc
PINK:LNBY
|
-0.312x |
|
CSX - Dusseldorf Stock Exchang
DU:CXR
|
0.130x |
|
MATADOR RES
BE:7MR
|
0.120x |
|
IRGRF
OTCGREY:IRGRF
|
N/A |
|
Grayscale Digital Large Cap Fund Ll
OTCQX:GDLC
|
-0.199x |
|
MOBA Network publ AB
ST:MOBA
|
0.084x |
|
Eros Resources Corp
OTCQB:EROSF
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Syros Pharmaceuticals Inc (2014–2023)
The table below shows the annual cash flow conversion efficiency of Syros Pharmaceuticals Inc from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $16.66 Million | $-109.71 Million | -6.584x | -583.42% |
| 2022-12-31 | $127.74 Million | $-123.06 Million | -0.963x | +17.52% |
| 2021-12-31 | $85.22 Million | $-99.54 Million | -1.168x | -84.39% |
| 2020-12-31 | $90.55 Million | $-57.36 Million | -0.633x | +16.75% |
| 2019-12-31 | $79.18 Million | $-60.25 Million | -0.761x | -48.33% |
| 2018-12-31 | $78.59 Million | $-40.31 Million | -0.513x | +25.08% |
| 2017-12-31 | $65.32 Million | $-44.73 Million | -0.685x | -36.15% |
| 2016-12-31 | $80.60 Million | $-40.54 Million | -0.503x | +25.65% |
| 2015-12-31 | $34.05 Million | $-23.03 Million | -0.676x | -240.43% |
| 2014-12-31 | $60.24 Million | $-11.97 Million | -0.199x | -- |